Global health science marketing and communications firm, SCORR Marketing, has released a new study, in partnership with Applied Clinical Trials, evaluating the extent to which collaborations occur in the life sciences what influences them
Scientists at the University of Washington (UW) have designed mini-protein binders on a computer platform, which are not naturally occurring and may potentially be possible drug candidates.
This diary entry from R&D software provider, IDBS, looks at how individuals, laboratories and external collaborators can make their work more accurate with the help of cloud-based software.
As pressure to get drugs to the human clinical trial stage increases more companies are looking to outsource not only non-core functions but major areas of R&D. Here, Praveen C. Surana, ELC Group, examines outsourcing projects in more detail.
The latest report from business information and analytics provider, GlobalData, has indicated that immune-oncology (IO) will become the fifth pillar of cancer treatment, joining surgery, radiotherapy, chemotherapy and other targeted treatments.
Recently, there has been a shift within the pharmaceutical industry veering its R&D away from the traditional corporate campuses and moving them to new collaborative biotech clusters. Nick Sutcliffe, discusses the risks and opportunities of the trend
Indivior, a speciality pharmaceutical company, has opened a $30 million research and development (R&D) centre in Hull, UK, to further advance its treatment innovation into the global addiction crisis.
Global pharmaceutical and biopharmaceutical open access capability platform, WuXi AppTec, has published a report on immunotherapy, identifying that smaller biotech firms and early-stage companies will be the biggest driver behind therapy innovation.
Dr Marisa Miraldo, associate professor in Health Economics at Imperial College Business School, London, discusses ways to accelerate innovation in healthcare for the benefit of patients, healthcare providers and industry.
